Cosmo
Manufacturing · Ireland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Riverside Ii Sir John Rogerson's Quay, D...Phone Number
+353 18170370Website
www.cosmopharma.comRevenue
$212 MillionStock Symbol
COPNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Cosmo
Cosmo Pharmaceuticals NV is a pharmaceutical company focused on becoming a leader in gastroenterology and dermatology. The company has developed a proprietary clinical pipeline targeting innovative treatments for gastrointestinal diseases and skin conditions, addressing unmet medical needs. With six approved drugs and two medical devices, Cosmo licenses its products to partners with strong marketing capabilities. Its mission includes providing improved healthcare solutions while engaging in sustainable practices.Explore more
Cosmo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cosmo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cosmo, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Cosmo had a recent Job posting/layoffs
Check if Cosmo has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cosmo
Earning: See what the market has to say on Cosmo recently announced quarterly report
Funding: Get notified immidiatlly once Cosmo has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Cosmo launches new products
Check out if Cosmo is spiking on competitors!
Recommended Actions
Find VP level buyers at Cosmo
Find more new buyers
Company Profile Activity
Activity Insights
Cosmo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cosmo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cosmo.
Cosmo Tech Stack
A closer look at the technologies used by Cosmo
Most Recent Scoops
Earnings
expects to exit 2026 with approximately 200 million in cash and investments, with no debt.
Financial Planning, Business Finance, Finance, Financial Strategy
Earnings
closed the year with 128.3 million euro in cash, with zero debt, and maintained its dividend.
Business Finance, Finance, Financial Operations
Project
plans to launch in the first European markets before summer, with partners Glenmark and Infectopharm completing pre-work. The company expects strong supply requirements from these partners this year.
Partnership
Earnings
expects estimated cash and equivalents at the end of 2026 to be approximately 200 million.
Financial Planning, Forecasting, Finance, Financial Strategy
Earnings
Earnings, Finance
Cosmo News & Media
Cosmo Pharmaceuticals (SWX:COPN): Assessing Valuation Following Recent Share Price Momentum
Shares of Cosmo Pharmaceuticals (SWX:COPN) have drawn interest lately as investors take a closer look at its recent performance. Over the past month, the stock is down 2%, but it remains up 17% for the past 3 months. See our latest analysis for Cosmo Pharmaceuticals. Looking at the bigger picture, Cosmo Pharmaceuticals’ share price return shows clear momentum. A hefty 17.3% gain over the last 90 days stands out against a modest 6% total shareholderCosmo Pharmaceuticals And Two More Top Dividend Stocks To Consider
In a week marked by cautious Federal Reserve commentary and looming political uncertainties, global markets experienced notable fluctuations, with U.S. stocks facing broad-based declines despite a late-week rally. As investors navigate these turbulent waters, dividend stocks often appeal for their potential to provide steady income streams amidst market volatility. When considering what makes a good dividend stock in such an environment, it's crucial to look for companies with strong...Cosmo Pharmaceuticals Appoints Chief Strategy Officer - Yahoo Finance
Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus on strategy-led growth and innovation. She will be reporting to the CEO. ...Cosmo Pharmaceuticals Appoints New Chief Financial Officer - Yahoo Finance
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cosmo
Sign Up For FreeTo access detailed company insights
Cosmo Pharmaceuticals NV is a pharmaceutical company focused on becoming a leader in gastroenterology and dermatology. The company has developed a proprietary clinical pipeline targeting innovative treatments for gastrointestinal diseases and skin conditions, addressing unmet medical needs. With six approved drugs and two medical devices, Cosmo lic... Read More
